Capricor shares five-year deramiocel data at DMD conference

June 26, 2026 9:05 AM

Capricor Therapeutics (NASDAQ: CAPR) presented five-year data from its HOPE-2 Open-Label Extension study of deramiocel, a cell therapy candidate for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found